IN THE UNITED STATES PATENT AND TRADEMARK OFFICE ATTORNEY DOCKET NO. 084335-0182

Applicant:

Takao ISOGAI et al.

Title:

FULL-LENGTH cDNA

Appl. No.:

10/777,288

Filing Date: 02/13/2004

Examiner:

Unassigned

Art Unit:

1653

INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR §1.56**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits, and within three (3) months of the mailing date of the foreign search report.

RELEVANCE OF EACH DOCUMENT

Any document listed on the attached PTO/SB/08 was cited as being relevant during the prosecution of the corresponding European application. A copy of the European Search Report is attached setting forth the portion of each document considered relevant by the examiner. The absence of a translation does not relieve the PTO from its duty to consider any submitted document (37 CFR §1.98 and MPEP §609).

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

September 6, 2005

Date

FOLEY & LARDNER LLP

Customer Number: 22428

Telephone:

(202) 672-5569

Facsimile:

(202) 672-5399

Respectfully submitted,
Miller
Reg No. 34,717

Stephen B. Maebius

Attorney for Applicant Registration No. 35,264

MODIFIED PTO/SB/08 (08-00) te through 10/31/2002, OMB 0651-0031

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for form 1449B/PTO				Complete if Known		
	INFORMATIO	N DISCLO	SURE O	PE	Application Number	10/777,288	
	STATEMENT			4	Riling Date	02/13/2004	
			(000		Time Named Inventor	Takao ISOGAI et al.	
			12 SEP	0 6 2005	Group Art Unit	1653	
	(use as many sh	neets as ne	cestagny)		xaminer Name	Unassigned	
Sheet	1	of	1 8/2	- 4G	Attorney Docket Number	084335-0182	
_		•					

U.S. PATENT DOCUMENTS							
Examiner Initials*	0	U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant	
	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No. ¹			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶			
	A1	ΕP	1 195 434	Α	Taisho Pharmaceutical Co.	04/10/2002				
	A2	wo	02/068652	Α	Curagen Corporation	09/06/2002				
	A3	wo	2004/016225	Α	Genentech, Inc.	02/26/2004				
	A4	wo	2004/024760	Α	Takeda Chemical Ind. Ltd.	03/25/2004				

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A5	Database EMBL, December 13, 2001, STRAUSBERG et al., "Homo Sapiens Solute Carrier Family 10 (Sodium/Bile Acid Cotransporter Family), Member 4 mRNA (cDNA Clone MGC: 29802 Image 4897519), Complete CDS," XP-002332592.	
	A6	DATABASE EMBL, December 1, 2001, STRAUSBERG et al., "Solute Carrier Family 10 (Sodium/Bile Acid Cotransporter Family), Member 4," XP-002332593.	
	A7	DATABASE EMBL, December 18, 2003, "Sequence 113 From Patent WO 02/068652," XP-002332594.	
	A8	DATABASE EPO PROTEINS, December 18, 2003, "Sequence 114 From Patent W0 02/068652," XP-002332595.	
	A9	DATABASE EMBL, September 9, 2003, YAMAMOTO, "Homo Sapiens cDNA FLJ44578 Fis, Clone 3NB692004045, Weakly Similar to Sodium/bile Acid Cotransporter," XP-002332596.	
	A10	DATABASE GENESEQ, May 20, 2004, "Human Tumour-Associated Antigenic Target (TAT) cDNA Sequence #69," XP-002332597.	
	A11	DATABASE GENESEQ, May 20, 2004, "Human Tumour-Associated Antigenic Target (TAT) Polypeptide #65," XP-002332598.	
···	A12	DATABASE GENESEQ, June 17, 2004, "Human TCH162 cDNA, Seq. ld 15," XP-002332599.	
	A13	DATABASE GENESEQ, September 16, 2004, "Novel Protein and its DNA," XP-002332600.	

Examiner	Date	
Signature	Considered	
	<u> </u>	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.